{"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}],"groups":[{"description":"Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity.\n\nsaracatinib: Given orally","id":"BG000","title":"Arm I"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"22","upperLimit":"79","value":"65"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Canada"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}